Israeli Expert Compares New US-Approved mRNA Flu Vaccine to COVID-19 Shots

Professor Tal Brosh, head of the Infectious Diseases Unit at Assuta Ashdod Hospital, discussed the newly approved mRNA flu vaccine in the United States during a radio interview on 103FM on August 9, 2026. He explained that the mRNA vaccine works by entering cells and prompting them to produce the protective agent for several days, a method he described as highly efficient and easier to manufacture than traditional egg-based vaccines.

Brosh noted that while the new vaccine has shown about 20% higher efficacy compared to standard flu vaccines, it was approved in the US only recently and is not yet registered in Israel. He expressed doubt that it would be relevant for the upcoming flu season due to timing but hoped it would be available in Israel next year. Regarding cost, he said the vaccine might not be cheaper initially due to development expenses, but overall mRNA vaccines are inexpensive and easy to produce and update.

He emphasized the importance of flu vaccination for all individuals aged six months and older, especially older adults and those with underlying health conditions, despite flu vaccines generally being less effective than vaccines for diseases like measles or tetanus. Brosh stressed that even with varying effectiveness, getting vaccinated with any available flu vaccine, whether standard or high-dose, remains crucial and should not be hindered by healthcare policy issues.